Efficacy of Simvastatin for Lowering Cholesterol in Non-Insulin Dependent Diabetic Patients with Hypercholesterolemia*

References

• Kanncl WB, Mc Gee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care. 1979: 2: 120–6.
   Google Scholar
• Jarrell RJ, Shipley MJ. Mortality and associated risk factors in diabetics. Ada Endocrinol. 1985; 111) (Suppl. 272): 21–6.
   Google Scholar
• Pan Wll, Cedrcs LB, Liu K el al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol. 19X6; 123: 504–16.
   Google Scholar
• Hanefeld M, Schulzc J, Fischer S, Julius V, Schmechel H, Hallcr H. The Diabetes Intervention Study (DIS): A cooperative multi-intervention trial with newly manifested type II diabetics: preliminary results. Monogr Atherosclerosis. 1985; 13: 98–103.
   Google Scholar
• Wilson PWF, Kanncl WB, Anderson KM. Lipids, glucose tolerance and vascular diseases: The Framingham Study. Monogr Atheroscherosis. 1985; 13: 1–11.
   Google Scholar
• Taskinen MR. Hyperlipidaemiaand diabeies: spectrum of lipid disorders in diabetes. In: Diabetes. Karkins, Zimmel & Chisholm (eds): Elsevier Science publishers B.V., New York 1988, 537–54.
   Google Scholar
• European NIDDM-Policy Group. A desk top for the management of non-insulin-dependent diabetes mellitus (NIDDM). Boehringer-Mannheim GmbH, Mannheim 1989.
   Google Scholar
• Roscngrcn A, Welin L.Tsipogianni A, Wilhelmscn L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle-aged diabctic men: a general population study. Br Med J. 1989; 299: 1127–31.
   Google Scholar
• Clifton-Bligh P. Miller NE, Nestel PJ. Changes in plasma lipoprotein lipids in hypercholesterolemia patients treated with the bile acid-sequestering resin, colestipol. Clin Sci. 1974; 47: 547–57.
   Google Scholar
• Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990; 13: 153–69.
   Google Scholar
• Garg A. Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med. 19X8; 318: 81–6.
   Google Scholar
• Yoshino G, Kazumi T. Iwai M. Long-term treatment of hypercholesterolemia non-insulin-dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis. 1989; 75: 67–72.
   Google Scholar
• Sasaki T. Kurala H, Nomura K, Ulsunomiya K, Ikeda Y. Amelioration of proteinuria with pravastatin in hypercholesterolemia patients with diabetes mellitus. Jpn J Med. 1990; 29: 156–63.
   Google Scholar
• Paolisso G, Sgambalo S, Dcriu S, Verza M. Varricchio M, D’Onofrio F. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur J Clin Pharmacol. 1991; 40: 27–31.
   Google Scholar
• Lie RF, Schmitz JM, Pierre KJ. Gochman N. Cholesteryloxydase based determination by continuous How analysis of total and free cholesterol in serum. Clin Chem. 1976; 22: 1627–30.
   Google Scholar
• BricoloG, David H. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem. 1973; 19:475–82.
   Google Scholar
• Lopez-Virella I IF, Stone P. Shclton E. ColwezJA. Cholesterol determination in high density lipoprotein separated by three different methods. Clin Chem. 1977; 23: 882–4.
   Google Scholar
• Hachem H. Raynal G, Favre G, Hanza M, Canal P. Sovla G. Dosage des apolipoprotdines AI el B st5-riques par immunoturbidimiitrie sur analyseurs centrifuges Cobas-BlO. Ann Biol Clin. 1985; 43: 885–90.
   Google Scholar
• Colwell JA. Platelets, endothelium and diabetic vascular disease. Diab Metabol. 1988; 14:512–8.
   Google Scholar
• Juhan-Vague I, Collen D. Hypofibrinolysis and atherothrombosis. Diab Metabol. 1988; 14:47983.
   Google Scholar
• Lipid Research Clinic Program. The Lipid Research Clinic Coronary Primary Preveniion Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251: 365–74.
   Google Scholar
• Miccoli R, Bertolotto A, Giovannitti MG el al. Simvastatin for lowering cholesterol levels in noninsulin-dependent diabetes mellitus and in primary hypercholesterolemia. CurTher Res. 1992; 51:6674.
   Google Scholar
• Zainbon S. Lapolla A, Sartore G el al. Long-term treatment with simvastatin in hypercholesterolemia non-insulin-dependent diabetic patients. Curr TherRes. 1992; 52: 221–9.
   Google Scholar
• Owens D, Stinson J. Collins P. Johnson A. Tomkin GH.Improvement in the regulation of cellular cholesterologenesis in diabetes: the effect of reduction in serum cholesterol by simvastatin. Diabetic Med. 1991; 8: 151–6.
   Google Scholar
• Expert panel national cholesterol education program. Report on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med. 1988; 148: 36–69.
   Google Scholar
• Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment Panel II). JAMA. 1993; 269: 3015–23.
   Google Scholar
• Tobcrt JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988; 62 : 28J-34J.
   Google Scholar
• Toberi JA. New developments in lipid-lowering therapy: ihe role of inhibitors of hydroxymethylglutarylcoenzyme A-reductase. Circulation. 1987; 76: 534–8.
   Google Scholar
• Marks J, Howard AN. A comparative study of gemfibrozil and clofibrate in the treatment of hyperlipidemia in patients with maturity-onset diabetes. Res Clin Forum. 1982; 4: 95–103.
   Google Scholar
• Gurian II, Aldersberg D. The effect of large doses of nicotinic acid on circulating and carbohydrate tolerance. Am J Med Sci. 1959; 237: 12–22.
   Google Scholar